We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Neurological Disorder Linked to Genetic Mutations

By LabMedica International staff writers
Posted on 04 Jan 2012
A gene has been detected that is linked to epilepsy in babies and movement disorders in older children. More...


The gene has been associated with the rare childhood neurological disorder known as paroxysmal kinesigenic dyskinesia with infantile convulsions or PKD/IC.

A large international team led by scientists at the University of California, San Francisco (UCSF; USA) studied ways that could help to improve the diagnosis of PKD/IC and may also help to explain other movement disorders, such as Parkinson's disease. The team has identified a perplexing gene in the brain called proline-rich transmembrane protein 2 (PRRT2). No knowledge exists about the function or ability of this gene, which bears little resemblance to anything else in the human genome.

The scientists conducted the study on a cohort of 103 families, which included one or more members with the PKD/IC manifestation. The investigators identified mutations in the PRRT2 gene that is present in the brain and spinal cord, during genetic testing of the families. The mutation causes the proteins that the PRRT2 gene encodes to shorten or to completely disappear from the individual's brain and spinal cord. According to the investigative team, the neurological symptoms may be caused due to a loss of neuronal regulation, meaning that when the genetic mutations cause the gene products to disappear, the nerve cells, which normally appear in those locations, may become overly excited, firing signals too frequently or strongly, which leads to the involuntary movements.

Louis Ptacek, MD, the senior author of the study, said, "This is both exciting and a little bit scary. Understanding the underlying biology of this disease is absolutely going to help us understand movement disorders in general." PKD/IC is a rare disorder in infants with epileptic seizures, affecting approximately one in every 100,000 children in the US, according to Prof. Ptacek's estimation. It commonly disappears within a year or two but often reemerges later in childhood as a movement disorder, which is characterized by sudden, startling, involuntary jerks when the children start moving. In some children just the thought of moving will cause them to jerk involuntarily. The disease is classified as idiopathic, which, is basically just another way of saying the cause is unknown. The study was published in the January 2012 issue of Cell Reports.

UCSF


Related Links:

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.